TerminatedPhase 2

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

Stopped: Sufficient clinical results obtained to support study endpoints.

United States2,228 participantsStarted 2016-12-21

Plain-language summary

This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.

Age range8 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Corneal thickness \< 375 microns measured by ultrasound or Pentacam.
✕. Contraindications or hypersensitivities to any study medications or their components.
✕. Pregnancy or breastfeeding.
✕. Any history of herpes simplex corneal disease in an eye to be treated.
✕. Nystagmus or any other condition that would, in the judgement of the investigator, prevent a steady gaze during the treatment.
✕. Inability to cooperate with diagnostic tests.
✕. Enrollment in another ophthalmic clinical trial.

Change From Baseline in Corrected Distance Visual Acuity (CDVA)

Timeframe: Baseline and 6 and 12 months

NCT IDNCT03029104

SponsorCxlusa

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-12-27

Results submitted2021-11-14